



Industry Veteran Carrie Powers Joins CHF Solutions, Inc. as Vice President of Marketing

March 12, 2018

EDEN PRAIRIE, Minn., March 12, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS), today announces the appointment of Carrie Powers, RN, as vice president of marketing.

Ms. Powers joins CHF Solutions with 12 years of leadership, management, and marketing experience within the interventional cardiology and interventional radiology markets. During her tenure at Vascular Solutions, she was the senior vice president of Marketing, and helped launch more than 50 medical devices, contributing to the consistent delivery of double-digit annual growth. Most recently, she served as the senior director of Clinical and Medical Affairs for the Interventional business unit for Teleflex Medical, which acquired Vascular Solutions in 2017. In this role, she was responsible for providing strategic direction for all clinical education programs, developing and managing key opinion leader relationships, providing clinical and medical expertise for new product development and M&A projects, assisting in the building of evidence generation programs, clinical trials, and working closely with the medical directors.

"Carrie's clinical background combined with her strategic focus from her previous marketing leadership roles brings unique and multi-faceted experiences to her new role at CHF Solutions," said Jim Breidenstein, chief commercial officer of CHF Solutions. "We look forward to applying her commitment and focus toward helping us meet our growth initiatives.

About CHF Solutions

CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis[®] therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

CONTACTS:

INVESTORS:

Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-

Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

[Primary Logo](#)

Source: CHF Solutions, Inc.